Sarcopenia and Juvenile Idiopathic Arthritis

NCT07634354 | Not Yet Recruiting

• 1 other identifier: PL26052
• Study Type: interventional
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

Juvenile idiopathic arthritis (JIA) is a rare chronic inflammatory rheumatic disease that begins during childhood and may persist into adulthood in many patients. In addition to joint pain, swelling, and long-term articular damage, chronic inflammatory diseases may also be associated with early sarcopenia, defined as a loss of muscle strength and muscle mass. While this association has been described in adult inflammatory rheumatic diseases, it has not been well studied in patients with JIA. The aim of this study is to screen for sarcopenia in adolescents and adults with JIA in France. Sarcopenia will be assessed using validated questionnaires, hand grip strength measured with a Jamar dynamometer, and body composition measured by dual-energy X-ray absorptiometry (DEXA). Completion of validated questionnaires will assess nutritional status, fatigue, physical activity, and functional impact. Socio-demographic and clinical data will also be collected from medical records. This multicenter cross-sectional study will be conducted between June 2026 and October 2027 in 11 French hospitals. Eligible participants are patients aged 15 to 40 years with JIA diagnosed according to ILAR criteria and followed in a French hospital. This study will provide the first estimate of sarcopenia prevalence among patients with JIA in France. It will also help identify factors associated with sarcopenia and its impact on daily functioning and quality of life. In the longer term, the findings may help clinicians better identify patients at risk and support earlier management focused on disease control, physical activity, and nutritional care.

Conditions

Juvenile Idiopathic Arthritis

Keywords

Juvenile idiopathic arthritis; Sarcopenia

Outcome Measures

Primary Outcomes (1)

• Sarcopenia

  A cross-sectional assessment of sarcopenia for each included patient will be performed at a participating hospital center: Performance of a hand grip test using a hand dynamometer (3 consecutive measurements on the dominant hand) and a whole-body DEXA scan with measurement of the appendiceal mass index Confirmation by the best grip test value \< -2 SD according to the patient's age and sex on the reference curves associated with a pathological whole-body DEXA (appendiceal mass index ≤ 7 kg/m2 for men, ≤ 5.5 kg/m2 for women)

  Day 1

Secondary Outcomes (4)

• Fatigue assessed by FACIT-F

  Day 1

• Physical activity assessed by IPAQ

  Day 1

• Functional disability assessed by HAQ-DI

  Day 1

• Health-related quality of life assessed by SF-12

  Day 1

Study Arms (1)

Patients with juvenile idiopathic arthritis

OTHER

Single group of adolescents and adults with juvenile idiopathic arthritis undergoing a standardized sarcopenia screening assessment at inclusion.

Other: Sarcopenia screening assessment

Interventions

Sarcopenia screening assessment OTHER

Participants will undergo a standardized single-visit assessment including hand grip strength measurement, whole-body DEXA scan for body composition, validated questionnaires, and collection of socio-demographic and clinical data from medical records.

Patients with juvenile idiopathic arthritis

Eligibility Criteria

• Age: 15 Years - 40 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Patients followed in French hospitals participating in the study for juvenile idiopathic arthritis, all forms combined, diagnosed according to the ILAR criteria defined in Edmonton in 2001
• Patients aged 15 to 40 years
• Affiliated to social security
• Agreeing to participate in the study and having given their written consent (signed consent form).
• In the case of a minor patient, the consent of the patient and their legal guardians is required.

You may not qualify if:

• Patient under legal guardianship
• Patient not covered by social security
• Pregnant woman
• Inability to perform a functional test required by the study (grip test or whole-body DEXA scan)
• Inability to understand the questionnaires

Sponsors & Collaborators

• CHU de Reims: lead

Study Sites (1)

Marie Muller

Reims, France

Location

MeSH Terms

Conditions

Arthritis, Juvenile; Sarcopenia

Condition Hierarchy (Ancestors)

Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases; Muscular Atrophy; Neuromuscular Manifestations; Neurologic Manifestations; Nervous System Diseases; Atrophy; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms; Signs and Symptoms

Central Study Contacts

Ambre HITTINGER-ROUX

CONTACT

03 10 73 67 07; ahittinger-roux@chu-reims.fr

Jean-Hugues SALMON

CONTACT

03 26 78 44 21; jhsalmon@chu-reims.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SCREENING
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 3, 2026
• First Posted: June 8, 2026
• Study Start: June 1, 2026
• Primary Completion (Estimated): October 1, 2027
• Study Completion (Estimated): October 1, 2027
• Last Updated: June 8, 2026

Record last verified: 2026-05

Locations

FR (1)